Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive T Cell Therapy for Adenovirus Infection After HSCT
NCT03378102Phase 1Recruiting
- Start
- Jan 2019
- Primary completion
- Dec 2028
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IFN-gamma-secreting HAdV antigen specific T cells in adenovirus infection. Primary endpoint: Number of patients with severe adverse events at 100 days. Started Jan 2019; status: recruiting.
02
Drugs
IFN-gamma-secreting HAdV antigen specific T cells
03
Conditions
adenovirus infection
Beyond the preview
Go deeper on NCT03378102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03378102.